Epidermolysis bullosa (EB) encompasses a group of inherited blistering skin disorders classified into three main subtypes of simplex, junctional and dystrophic. In recent years there have been substantial advances in our understanding of the molecular basis of these conditions and in the management of such patients. In spite of this progress, squamous cell carcinoma (SCC) is still a major cause of morbidity and mortality, particularly in Hallopeau-Siemens recessive dystrophic EB. The reason why dystrophic EB patients readily develop SCC with such a poor prognosis remains a mystery. This article reviews the epidemiology of cancer in inherited EB and also discusses the clinical features, histological assessment and treatment options of SCC in EB.
Introduction
Epidermolysis bullosa (EB) is a heterogenous group of skin disorders associated with widespread blisters, erosions and chronic wounds. Inherited EB is classified into three main subtypes ) simplex, junctional and dystrophic, based on ultrastructural levels of skin cleavage. 1 The epithelial fragility occurs at or close to the dermalepidermal junction and over the past 10 years research has led to the identification and characterization of the genes for many of the structural proteins that secure adhesion between the epidermis and the underlying dermis. 1 In addition to an increased understanding of the molecular basis of EB, recent years have also seen substantial clinical advances in patient management. These include improved neonatal assessment, nutrition and wound care with an emphasis on multidisciplinary team management. However, one of the major clinical issues still afflicting EB sufferers is the complication of cutaneous squamous cell carcinoma (SCC). This review discusses the epidemiology, clinical features and management of malignancy in EB with a particular emphasis on cutaneous SCC in dystrophic EB (DEB).
What is the risk of developing SCC in different types of EB?
Cutaneous SCC is most apparent in recessive DEB. In Hallopeau-Siemens recessive DEB the cumulative risk is 76.5% by the age of 60 years 2 compared with a lifetime risk of cutaneous SCC in the general non-EB United States population of 9-14% among men and 4-9% in women.
3 Table 1 illustrates the cumulative risk of SCC in all subtypes of EB and was adapted from the largest published series from the United States National Epidermolysis Bullosa Registry (NEBR) with more than 1995 registered EB sufferers. It is important to note that the increased risk of developing SCC starts in teenage years.
Although this series lacked examples of SCC arising in junctional EB (JEB), such cases of SCC have also been reported. [4] [5] [6] [7] Notably, these patients developed SCC later in life when compared to recessive DEB patients. In addition, a case of multiple keratoacanthomas in a patient with junctional EB has been documented. 8 Is there a greater risk for EB sufferers developing basal cell carcinoma?
Basal cell carcinoma (BCC) in EB is relatively uncommon when compared to the non-EB general population, in whom the lifetime cumulative risk is 28-33% (for a person born in North America in 1994). 9 In 
What about melanoma risk in EB?
Clinically atypical melanocytic lesions are known to occur in EB, especially in areas of recurrent blistering and may resemble malignant melanoma. 10, 11 Even though architectural and histological atypia have been reported, these naevi in EB have not been reported to undergo malignant transformation. 10 Malignant melanoma is uncommon but poses a significant risk. NEBR data analysis reveals a cumulative risk by age 60 years of 1.72% in EBS (n ¼ 1164), 2.06% in dominant DEB (n ¼ 271), 2.52% in Hallopeau-Siemens recessive DEB (n ¼ 100), 0.67% in non-Hallopeau-Siemens recessive DEB (n ¼ 181) and no cases in 168 JEB patients. 2 In 1996 the lifetime risk in the non-EB United States general population of developing malignant melanoma was quoted to be 1 in 87 (1.15%). 12 The relatively high risk in EBS, dominant DEB and HallopeauSiemens recessive DEB may be an effect of the small numbers. Of particular interest in the EB series, was the occurrence of malignant melanoma in three unrelated children with recessive DEB, aged 3, 6 and 11 years.
Do EB patients have an increased risk of extracutaneous malignancy?
There are case reports of extracutaneous malignancies in EB, including SCC of the hard palate 13 and osteogenic sarcoma of the tibia. 14 The epithelial lining of the oesophagus and intestine in JEB and DEB is subject to chronic inflammation and damage. One might expect that this increases the risk of epithelial metaplasia and progression to malignancy. Indeed, SCC arising in the oesophagus has been documented in a 57-year-old woman with the inversa form of recessive DEB. 15 However, the NEBR data analysed the frequency of internal malignancies in 168 JEB sufferers and 630 DEB sufferers and found no significant differences when compared to 1169 EBS sufferers, or the general population.
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How often should DEB patient skin be examined for possible malignancy and what clinical features should be looked for?
SCC in DEB has a predilection for limbs and over bony prominences, 16, 17 sites where blistering and scarring are most pronounced ( Fig. 1) , and there is no obvious relationship with sun exposure. The same is true for the relatively few cases of SCC complicating JEB. [4] [5] [6] [7] SCC in DEB can also have a variety of clinical manifestations (Figs 2-4). Assessment can be difficult, as the appearances are often similar to the typical chronic ulceration, scarring and crusting widely seen in DEB. Therefore, there should be a low threshold to biopsy chronic nonhealing ulcers and hyperkeratotic nodules or plaques. Persistent hyperkeratotic crusting should be lifted off so that underlying cutaneous changes can be assessed. As with burn scar cancers, tumours often start at an ulcer margin and only one portion of the ulcer may undergo malignant change, whilst the rest remains a non-healing inflamed area. [18] [19] [20] Therefore, it is often essential to perform multiple biopsies to avoid missing occult malignancy. In addition, regional lymph node examination is important because if lymphadenopathy is detected it may warrant a fine needle aspiration or lymph node biopsy. At St John's Institute of Dermatology we review DEB and non-Herlitz JEB patients every 6 months in a Ôcombined EBÕ clinic, where the input of different specialists is provided. These include nurse specialists, dieticians, a dentist, physiotherapists and plastic surgeons. Additional clinical input from ophthalmologists and gastroenterologists is often also included. Ideally, the entire skin should be examined on these occasions. Although it is time-consuming and often inconvenient for the patient, it is necessary to remove and reapply the extensive dressings. Early detection is essential in improving prognosis; however, multiple primaries occur in more than 60% of DEB patients 21 ( Figs 5 and 6 ) and therefore the outcome is variable and often unpredictable.
What is the histology and biological behaviour of these EB-associated SCCs?
Most EB-associated SCCs are well-differentiated. 16 However even well-differentiated SCCs in EB can result in secondary spread and it is not possible to predict biological tumour behaviour simply on the basis of histological grade alone. With respect to immunohistochemical markers, Slater et al. 22 studied p53 protein expression in 23 SCCs in six recessive DEB patients using an antibody to p53. Fourteen out of 15 welldifferentiated tumours showed a complete absence of immunohistochemical anti-p53 labelling, but in the moderately and poorly differentiated tumours, 63% (5 ⁄ 8) of SCCs demonstrated positive labelling. Of the three patients in the latter group, one died from disseminated tumour and another had widespread metastases. Therefore, although immunohistochemical p53 protein expression may correlate with poorer tumour differentiation and tumour aggressiveness, in DEB SCCs, it is of limited clinical value.
Other histological subtypes of SCC described in EB include spindle cell and verrucous carcinomas. 16 On occasions, the histopathology can be misleading, as illustrated by a case with nodular skin tumours, showing an angiosarcomatous histology. 23 However, positive anti-keratin immunostaining established that this was actually an SCC coexisting with local lymphodema from lymphatic obstruction.
From a practical perspective, biopsies of lesions suspected to be SCC in EB should ideally be interpreted by a histopathologist experienced in viewing EB specimens, as well-differentiated SCCs in this context can be difficult to distinguish from pseudoepitheliomatous hyperplasia, a finding often noted in non-malignant EB ulcer margins or sites of chronic wound healing.
What are the roles of surgery, radiotherapy and chemotherapy in the management of SCCs in EB?
At present, treatment of SCCs in EB usually comprises surgical excision. However, clear excision margins do not always ensure a cure. One Hallopeau-Siemens recessive dystrophic EB sufferer in our unit developed a well-differentiated SCC on his left shin at the age of 32 years. Despite two excisions both reporting complete clearance and no clinical signs of a second primary tumour, 6 months after the first tumour he developed enlarged nodes in the left groin, which were consistent with metastatic SCC on fine needle aspiration. Review of the original histological sections revealed no initial evidence of lymphatic or vascular invasion by the tumour. Surgical excision of SCCs is the most practical management option as clinically, several premalignant and nonmalignant lesions may look similar and histological analysis is the only means of establishing an accurate diagnosis. Most surgical approaches aim for the macroscopic clear margins (with subsequent histological confirmation). Microscopically controlled excision (Mohs' technique) has been used to treat SCC in EB, 5, 24 but there is no data confirming whether this technique leads to a better outcome in terms of morbidity or mortality than wide excision. Radiotherapy can be beneficial in treating associated lymphadenopathy 16 as well as some primary lesions. 17 Bastin et al. 25 reviewed 14 SCCs irradiated in 12 DEB Figure 6 (a) Low (· 20) and (b) higher (· 400) magnification views of the light microscopic appearances of a poorly differentiated SCC from a further primary on the lower leg, that also occurred in the same patient in Fig. 3 . This biopsy was taken from an ulcerated site and the small islands of SCC are seen alongside prominent neovascularization typical of chronic ulcers. It is important to be aware of the possible epithelial malignancy in such cases of DEB biopsies and to perform anticytokeratin immunohistochemical staining if there is any diagnostic dilemma. Epidermolysis bullosa and cancer • R. Mallipeddi patients, nine of whom were recessive (the other three did not have a documented inheritance pattern). Total radiation doses ranged from 12 to 60 Gy (median 45 Gy) delivered over 9-47 days. Overall 54% (6 ⁄ 11) irradiated tumours showed a partial response with measurable reduction in tumour volume, 46% (5 ⁄ 11) had no response and three site responses were not described. However, there was poor wound healing and skin erosions as the total dose approached 45 Gy. It was evident that there was a narrow therapeutic index between tumour and normal skin tissue radiation tolerance, and therefore when using radiotherapy, it is essential to carefully design portal fields to minimize normal skin irradiation. Due to its toxicity, systemic chemotherapy is generally avoided and there are only three reports of its use in SCC associated with DEB in which outcome was documented. 26, 27 Two cases of metastatic SCC were treated with intravenous cisplatin-based chemotherapy. 26 Both were female in their 20s with recessive DEB. One was given eight weekly courses of cisplatin (20 mg ⁄ m 2 ) and the other received four courses of cisplatin (85 mg ⁄ m 2 on day 1) and fluorouracil (1000 mg ⁄ m 2 over 24 h on days 1-4) 1 week every month. There was a partial response in terms of reduction in axillary lymphadenopathy and no significant mucocutaneous, haematological, gastrointestinal or renal toxicity. The former chose to discontinue therapy and died 3½ weeks later whereas the latter underwent resection of a chest lesion and right axillary lymph nodes, and was alive 1 year later. No subsequent follow-up data has been reported. Intra-arterial methotrexate has been used in one case of metastatic SCC on the right foot in a 47-year-old male with DEB. 27 Treatment was effective in reducing tumour and lymph node bulk, but induction of pancytopaenia led to sepsis and death. In our unit we have treated one case of a 24-year-old female with recessive DEB and metastatic SCC with two cycles of cisplatin and fluorouracil. One cycle involved cisplatin 75 mg ⁄ m 2 on day 1 and fluorouracil 187.5 mg ⁄ m 2 twice daily on days 1-4 followed by a 3-week gap. Higher doses were not possible because of diarrhoea. A necrotizing left groin SCC in this patient had already been treated with radiotherapy (45 Gy in 20 fractions) that resulted in some reduction in tumour bulk. Although the additional chemotherapy did not produce any significant toxicity, it did not result in any measurable clinical benefit. The patient died 3 months later. Although the evidence is limited, cisplatin-based chemotherapy may be of benefit in a palliative setting and does not seem to produce significant myelosuppression or mucocutaneous toxicity.
Why are DEB sufferers at such a high risk of developing cutaneous SCCs?
Why DEB sufferers readily develop SCC with such a poor prognosis is still unknown, although clinically the risk of developing SCC appears to parallel the severity and extent of ulceration and scarring in the skin. A number of aetiological factors may be important. One theory has proposed that repetitive tissue ulceration leads to a loss of cellular memory and progressively less cellular differentiation, promoting tumour development (Goldberg's tissue stress theory).
28 EB keratinocytes may have a premalignant potential and indeed growth activated keratinocytes have been found in recessive DEB, in both recently healed wounds and wounds that had been healed for over 2 years. 29 These growth activated keratinocytes could promote tumourigenesis via a cytokine stimulus acting through epidermal-dermal signalling. Fibroblast growth factor has been implicated to cause increased collagenase in recessive DEB 30 and could be an example of such a cytokine trigger.
In addition there may be a diminished immune surveillance of tumour cells in EB. In vitro studies have shown that patients with more severe forms of EB have reduced numbers of non-functional natural killer cells 31 as well as reduced peripheral mononuclear cell cytokine production. 32 There is currently a lack of information regarding the cell biology of SCC in EB, especially with regard to cancer-related gene expression or mutation analyses. However, some parallel observations might be drawn from published studies, for example in SCCs developing in other cicatrizing dermatoses. One study has shown that when comparing 21 burn-related SCCs with 50 conventional ultraviolet-induced SCCs, there was a higher incidence of Fas gene mutations in the former (14.3% vs. 0%). 33 Fas is widely expressed in normal and neoplastic cells, and the Fas-Fas ligand system is a major pathway for apoptotic induction in cells and tissues. 34 A mutant Fas may protect the tumour cells from undergoing apoptosis, allowing malignancy to develop. Although this offers a further possible explanation for scar associated cutaneous SCC, with relevance to EB tumours, the Fas gene has not been analysed in EB thus far.
There may also be biological markers that reflect an aggressive metastatic potential in SCCs. Shimuzu et al. 35 showed that epidermal growth factor receptor (EGFR) was more strongly expressed (using immunohistochemistry) in lymph node metastases of SCC when compared to primary cutaneous lesions. EGFR was not detectable in normal skin and the inference was that EGFR might confer metastatic potential in cutaneous SCC. Again this has not been assessed in EB-associated SCC.
Conclusions
Of all cutaneous malignancies, SCC is the only one with a vastly greater prevalence in EB sufferers compared with the non-EB population. This is a major cause of morbidity and mortality, with over 55% of HallopeauSiemens recessive DEB sufferers dying from SCC by the age of 40 years. 2 The aetiology is still unclear and ongoing work analysing expression profiles (using microarray analysis) and creation of relevant animal models may provide fresh insight into the epidermal and dermal cell biology of EB SCCs. This will hopefully lead to the discovery of new biological markers and subsequent development of better treatments. Nonetheless, in current practice, it is important to regularly assess the skin of these patients, particularly examining chronic ulcers and hyperkeratotic nodules or plaques, as well as having a low threshold for skin biopsy.
